Fulgent Genetics (FLGT) Q4 2024 earnings summary

Executive summary

• Achieved Q4 2024 core revenue growth of 14% year-over-year and 6% sequentially, with full year 2024 core revenue at $281.2 million, up 7% from 2023.

• Ended 2024 with $828.6 million in cash, cash equivalents, restricted cash, and marketable securities.

• Laboratory Services and precision diagnostics showed strong growth, with anatomic pathology and new product launches contributing.

• Therapeutic development advanced, with FID-007 in phase II and FID-022 cleared for phase I trials.

• Continued investment in business growth, technology, and sales team expansion.

Financial highlights

• Q4 2024 total revenue was $76.2 million; core revenue grew 14% year-over-year to $76.0 million.

• Full year 2024 GAAP loss was $42.7 million ($1.41 per share); non-GAAP income was $15 million ($0.49 per share).

• Q4 GAAP gross margin was 41.8%; non-GAAP gross margin was 44.2%.

• Adjusted EBITDA income for Q4 was $0.8 million; full year adjusted EBITDA loss was $2.8 million.

• Cash from operations was $25 million in Q4 and $21.1 million for the full year.

Outlook and guidance

• 2025 core revenue guidance is $310 million, representing 10% year-over-year growth.

• Expected 2025 revenues: $187 million from precision diagnostics, $106 million from anatomic pathology, $17 million from BioPharma services.

• Non-GAAP gross margins for 2025 expected to slightly exceed 40%; non-GAAP operating margin expected at approximately -15%.

• Anticipated 2025 GAAP EPS loss of $1.95 per share; non-GAAP net loss of $0.65 per share.

• Projected 2025 year-end cash position of $780 million, subject to M&A or repurchases.